DK0786255T3 - Fremgangsmåde til forbedring af tolerancen for allotransplantater og xenotransplantater ved administration af et LFA-3- eller CD2-bindingsprotein - Google Patents
Fremgangsmåde til forbedring af tolerancen for allotransplantater og xenotransplantater ved administration af et LFA-3- eller CD2-bindingsproteinInfo
- Publication number
- DK0786255T3 DK0786255T3 DK96117245T DK96117245T DK0786255T3 DK 0786255 T3 DK0786255 T3 DK 0786255T3 DK 96117245 T DK96117245 T DK 96117245T DK 96117245 T DK96117245 T DK 96117245T DK 0786255 T3 DK0786255 T3 DK 0786255T3
- Authority
- DK
- Denmark
- Prior art keywords
- lfa
- administering
- allotransplants
- xenografts
- binding protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70507—CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70528—CD58
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77270591A | 1991-10-07 | 1991-10-07 | |
US85070692A | 1992-03-12 | 1992-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0786255T3 true DK0786255T3 (da) | 2002-04-15 |
Family
ID=27118640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK96117245T DK0786255T3 (da) | 1991-10-07 | 1992-10-06 | Fremgangsmåde til forbedring af tolerancen for allotransplantater og xenotransplantater ved administration af et LFA-3- eller CD2-bindingsprotein |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP0786255B1 (es) |
JP (2) | JPH07502495A (es) |
AT (1) | ATE210454T1 (es) |
AU (1) | AU678141B2 (es) |
CA (1) | CA2120731C (es) |
DE (1) | DE69232295T2 (es) |
DK (1) | DK0786255T3 (es) |
ES (1) | ES2169783T3 (es) |
WO (1) | WO1993006852A2 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07502496A (ja) * | 1991-10-07 | 1995-03-16 | バイオゲン インコーポレイテッド | Cd2/lfa−3相互作用の阻害剤を用いる抗原提示細胞による皮膚障害の予防または治療の方法 |
US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
AU2006202939B2 (en) * | 1994-03-08 | 2008-11-20 | Dana-Farber Cancer Institute, Inc. | Methods of modulating T cell unresponsiveness |
DK0749323T3 (da) * | 1994-03-08 | 2001-02-05 | Dana Farber Cancer Inst Inc | Fremgangsmåder til modulering af T-celle-anergi |
US6001651A (en) * | 1998-03-20 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense modulation of LFA-3 |
EP1637155A1 (en) * | 1998-08-31 | 2006-03-22 | Biogen Idec MA Inc. | Method of mudulating memory effector T-cells using a CD2-binding agent, and compositions |
EE200100123A (et) * | 1998-08-31 | 2002-06-17 | Biogen, Incorporated | CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon |
AU2980900A (en) | 1999-02-04 | 2000-08-25 | General Hospital Corporation, The | Methods for human allografting |
CA2454618C (en) | 2001-07-24 | 2012-04-03 | Biogen Idec Ma, Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
KR20050082389A (ko) * | 2004-02-18 | 2005-08-23 | 메덱스젠 주식회사 | 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물 |
WO2005115436A1 (en) | 2004-05-07 | 2005-12-08 | Astellas Us Llc | Soluble lfa-3 polypeptide for treating viral disorders |
CA3094756A1 (en) * | 2018-03-29 | 2019-10-03 | Pfizer Inc. | Lfa3 variants and compositions and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE260880T1 (de) * | 1986-09-11 | 1988-11-03 | Dana-Farber Cancer Institute, Inc., Boston, Mass., Us | Verfahren zur ausloesung der zytotoxizitaet. |
CA1326940C (en) * | 1987-02-26 | 1994-02-08 | Michael Dustin | Purification of lfa-3 |
US4956281A (en) * | 1987-06-03 | 1990-09-11 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3 |
US5185441A (en) * | 1988-08-26 | 1993-02-09 | Biogen, Inc. | Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3 |
WO1990008187A1 (en) * | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
WO1991011194A1 (en) * | 1990-01-24 | 1991-08-08 | Biogen, Inc. | Lfa-3 as a vaccine adjuvant |
ATE193724T1 (de) * | 1991-03-12 | 2000-06-15 | Biogen Inc | Cd2 bindender bereich für das lymphocyten- funktion assoziierte antigen-3 |
JPH07502496A (ja) * | 1991-10-07 | 1995-03-16 | バイオゲン インコーポレイテッド | Cd2/lfa−3相互作用の阻害剤を用いる抗原提示細胞による皮膚障害の予防または治療の方法 |
-
1992
- 1992-10-06 AT AT96117245T patent/ATE210454T1/de active
- 1992-10-06 ES ES96117245T patent/ES2169783T3/es not_active Expired - Lifetime
- 1992-10-06 EP EP96117245A patent/EP0786255B1/en not_active Expired - Lifetime
- 1992-10-06 DK DK96117245T patent/DK0786255T3/da active
- 1992-10-06 JP JP5507247A patent/JPH07502495A/ja active Pending
- 1992-10-06 CA CA002120731A patent/CA2120731C/en not_active Expired - Fee Related
- 1992-10-06 DE DE69232295T patent/DE69232295T2/de not_active Expired - Lifetime
- 1992-10-06 AU AU28891/92A patent/AU678141B2/en not_active Ceased
- 1992-10-06 EP EP92922682A patent/EP0607353A1/en not_active Ceased
- 1992-10-06 WO PCT/US1992/008754 patent/WO1993006852A2/en not_active Application Discontinuation
-
2002
- 2002-07-25 JP JP2002216736A patent/JP2003128579A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2003128579A (ja) | 2003-05-08 |
ES2169783T3 (es) | 2002-07-16 |
AU2889192A (en) | 1993-05-03 |
DE69232295T2 (de) | 2002-07-18 |
EP0786255B1 (en) | 2001-12-12 |
AU678141B2 (en) | 1997-05-22 |
CA2120731A1 (en) | 1993-04-15 |
CA2120731C (en) | 2008-08-19 |
JPH07502495A (ja) | 1995-03-16 |
ATE210454T1 (de) | 2001-12-15 |
WO1993006852A2 (en) | 1993-04-15 |
WO1993006852A3 (en) | 1993-07-22 |
DE69232295D1 (de) | 2002-01-24 |
EP0607353A1 (en) | 1994-07-27 |
EP0786255A1 (en) | 1997-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0786255T3 (da) | Fremgangsmåde til forbedring af tolerancen for allotransplantater og xenotransplantater ved administration af et LFA-3- eller CD2-bindingsprotein | |
DK0527835T3 (da) | Doseringsform til afgivelse af et anti-Parkinsonmiddel | |
DK0621786T3 (da) | Induceret tolerance over for xenotransplantater | |
BR9915852A (pt) | Conjugado de hapteno-portador para tratamento e prevenção do vìcio da nicotina | |
FI963424A (fi) | Menetelmä terapeuttisesti aktiivisten tiofeenisulfonamidien valmistamiseksi | |
DK651088A (da) | Konjugater af laegemidler og monoklonale antistoffer | |
DK0751781T3 (da) | Anvendelse af monoklonale antistoffer eller oplöselige oligomere ligander til fremstillingen af et medikament til forebyggelse eller behandling af neoplastiske sygdomme | |
DK0476044T3 (da) | Anvendelse af IGF1 eller IGF2 til fremstilling af et lægemiddeltil behandling af amyotrof, lateral sklerose | |
DE69115441D1 (de) | Injektionsspritze | |
EP0330227A3 (en) | Derivatives of soluble t-4 | |
DE69010206D1 (de) | Stabilisierte protein- oder peptidkonjugate. | |
IT8819961A0 (it) | Dispositivo protesico composito modulare di gamba e piede. | |
RU99109594A (ru) | Способы и композиции для иммуномодуляции | |
DK0740650T3 (da) | Codrugs som metode til styret transport af lægemiddel | |
DE69434121D1 (de) | Pharmazeutische zusammensetzung zur immunstimulierenden therapie | |
DK0546076T3 (da) | Anvendelse af anti-ICAM antistoffer til fremstilling af et lægemiddel til behandling af endotoksiskshock | |
DK164441C (da) | Anvendelse af et piperidinderivat til fremstilling af et farmaceutisk praeparat til behandling af smertetilstande | |
DK122391D0 (da) | Terapeutisk aktiv, substitueret benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme | |
DK0601052T3 (da) | Terapeutisk fremgangsmåde til behandling af IDDM | |
BG60101A3 (en) | Method for preparing of 4-fluoro-2-[[(4-methoxy-2-pyridinyl)methyl]thionil]-1h-benzimidazo le | |
AU3757789A (en) | Method for delivery of therapeutic agents to target brain tissue using monoclonal antibody conjugates | |
NO892015L (no) | Fremgangsmaate for fremstilling av et legemiddel. | |
PT89224A (pt) | Processo para a preparacao de peptidos para o bloqueamento da actividade do pai-1 no sangue humano e sua utilizacao na preparacao de anticorpos | |
AU7178298A (en) | Magnetic resonance blood pool agents | |
Hoyer et al. | Influence of renal transplantation in rats on glomerular and tubular immune complexes |